TG Therapeutics Inc (FRA:NKB2)
€ 39.7 -5 (-11.19%) Market Cap: 6.48 Bil Enterprise Value: 6.69 Bil PE Ratio: 16.15 PB Ratio: 12.13 GF Score: 80/100

Q2 2026 TG Therapeutics Inc Earnings Call Transcript

Aug 03, 2026 / 12:30PM GMT
Release Date Price: €44.7 (-2.83%)
Operator

Greetings. Welcome to TG Therapeutics second-quarter conference call. (Operator Instructions) Please note, this conference is being recorded. At this time, I'll turn the conference over to Jenna Bosco, Chief Communications Officer. Thank you. You may begin.

Jenna Bosco
TG Therapeutics Inc - Chief Communications Officer

Thank you. Welcome, everyone, and thank you for joining us this morning. I'm Jenna Bosco, and with me to discuss TG Therapeutics' second-quarter 2026 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercial Officer; and Sean Power, our Chief Financial Officer. Following our safe harbor statement, Mike will begin with an overview of our recent corporate developments. Adam will provide an update on our commercial efforts, and Sean will review our financial results before we open the call for Q&A.

Before we begin, I would like to remind everyone that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot